The use of bevacizumab is correlated with improved post-progression survival in advanced recurrent ovarian cancer.
Shintaro YanazumeTakashi UshiwakaMika FukudaShinichi TogamiMasaki KamioHiroaki KobayashiPublished in: Japanese journal of clinical oncology (2021)
The continuous use of bevacizumab beyond progressive disease improves post-progression survival suggesting its important role in first-line and recurrence treatment for ovarian cancer.